At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 527 enrolled
Drug / intervention
Alogliptin and metformin +2 moredrug
Likely dose
Alogliptin and metformin 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin and metformin and Metformin for Diabetes Mellitus. Completed, enrolled 527 participants across 56 sites in 17 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesArgentina, Australia, Brazil, Chile, Czechia, Germany, Guatemala, Hungary, India, Mexico, Netherlands, New Zealand, Peru, Poland, South Africa, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2006
Enrollment StartMar 2006
Primary CompletionJun 2007
TodayJul 2026
First PostedFeb 3, 2006
Enrollment StartMar 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.4 years ago
Interventions
Alogliptin and metformindrug
Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
Alogliptin and metformindrug
Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
Metformindrug
Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.